<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">
Blogs

CU Cancer Center News and Stories

Climate Science

COVID-19    Melanoma    Climate Science

Sun protection strategies for COVID19 outdoor recreation

During COVID19, getting outside for socially distanced activities is one of the few forms of available recreation. But more people getting out also means more sun exposure, and so during Skin Cancer Awareness Month, University of Colorado Cancer Center reached out to one of our members, Neil Box, PhD, president of the Colorado Melanoma Foundation, to learn about the risks and how to stay safe.


Author Cancer Center | Publish Date May 11, 2020
Full Story

CU Cancer Center In the News

Cure Today

Caring for Patients with Sarcoma is a Team Effort, Expert Says

news outletCure Today
Publish DateJuly 12, 2024

University of Colorado Cancer Center member Dr. Steven Thorpe emphasizes the collaborative nature of treating soft tissue and bone sarcomas, highlighting the multidisciplinary efforts at CU School of Medicine's Department of Orthopedics and Children’s Hospital Colorado. He underscores the goal of not only curing the disease but also preserving function through advanced surgical techniques and modern therapies, ensuring patients maintain quality of life post-treatment. Thorpe stresses the importance of long-term outcomes, tailoring treatments to support patients’ aspirations beyond their cancer journey, especially for pediatric cases.

Full Story
OncLive

The Role of mTOR/Aurora A Kinase Combination Therapy Requires Further Elucidation in Solid Tumors

news outletOncLive
Publish DateJuly 08, 2024

CU Cancer Center member S. Lindsey Davis, MD, highlighted that the combination therapy of sapanisertib and alisertib showed marginal clinical benefit for patients with advanced solid tumors, correlative analyses suggested that apoptotic response and tumor immune cell infiltrate might influence clinical outcomes. The phase 1b study's expansion cohort indicated some positive outlying responses among patients and underscore the need for further research to tailor treatments for standout patients and explore rational combinations to enhance efficacy.

Full Story
News Medical

Study shows effectiveness of treating pancreatic cancer patients with chemotherapy before surgery

news outletNews Medical
Publish DateJune 19, 2024

A new study led by University of Colorado Cancer Center member Marco Del Chiaro, MD, PhD, reveals that nearly 5% of pancreatic adenocarcinoma patients achieved a pathological complete response (pCR) after pre-surgical chemotherapy or chemoradiotherapy. This significant finding indicates that patients with pCR have a 63% five-year survival rate, compared to 30% for those without pCR, suggesting the potential for tailored treatments to improve outcomes.

Full Story
Cancer Network

Liso-cel May Show Benefit in Earlier Therapy Lines for Lymphoma Subgroups

news outletCancer Network
Publish DateJune 14, 2024

In a conversation at the 2024 European Hematology Association Congress, CU Cancer Center member Manali Kamdar, MD, discussed potential future research on lisocabtagene maraleucel (liso-cel; Breyanzi) for mantle cell lymphoma (MCL) and other lymphoma subgroups. She highlighted findings from the phase 1 TRANSCEND NHL 001 trial, noting improved efficacy and safety in patients with fewer prior therapies and non-refractory disease, suggesting liso-cel's utility in earlier treatment lines and specific lymphoma subgroups.

Full Story